SYDNEY: Recce Pharmaceuticals Ltd announced the Board of Directors has unanimously appointed James Graham to the role of Chief Executive Officer.
Recce Pharmaceuticals Non-Executive Chairman Dr John Prendergast said, “James has demonstrated innate entrepreneurial and commercial skills that have been instrumental to the expansion of the Company. As James takes on his new role, the Board is confident in his ability to drive growth of the company’s expanding commercial opportunities and clinical initiatives. James’ appointment reflects his significant contributions to the business with an array of opportunities we are most excited about, now and into the future”.
Mr. Graham has a background in marketing, business development and commercialization of early stage technologies. He will continue to serve as a Director on the Board.
Chief Executive Officer James Graham said, “Our business has long been a sum of all parts and is my privilege to lead such an oustanding team. With several critical near-term milestones pending, including the commencement of our Phase I clinical trial, a Western Australia Health Department Topical Burns Wound Study submission and SARS-CoV-2 antiviral studies active around the world -it’s a promising time for our business. I look forward to working with the team to build on the Company’s progress in the pursuit to unlock the full clinical and commercial potential in the time ahead.”
Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of New Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.